Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAT-007 in advanced solid tumors
NCT02538432Phase 2Withdrawn
- Sponsor
- University of Maryland, Baltimore
- Start
- Jun 2017
- Primary completion
- Dec 2019
01
Overview
A Phase 2 trial of grapiprant in prostate cancer (PCa), breast cancer, non-small cell lung cancer (NSCLC), sponsored by University of Maryland, Baltimore. Planned start Jun 2017; status: withdrawn.
02
Drugs
grapiprant
03
Conditions
prostate cancer (PCa)breast cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02538432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02538432.